Mostrar registro simples

Biological variation estimates of Alzheimer’s disease plasma biomarkers in healthy individuals

dc.contributor.authorBrum, Wagner Scheerenpt_BR
dc.contributor.authorAshton, Nicholas J.pt_BR
dc.contributor.authorSimrén, Joelpt_BR
dc.contributor.authorDi Molfetta, Guglielmopt_BR
dc.contributor.authorKarikari, Thomas K.pt_BR
dc.contributor.authorBenedet, Andréa L.pt_BR
dc.contributor.authorZimmer, Eduardo Rigonpt_BR
dc.contributor.authorLantero-Rodriguez, Juanpt_BR
dc.contributor.authorMontoliu-Gaya, Laiapt_BR
dc.contributor.authorJeromin, Andreaspt_BR
dc.contributor.authorAarsand, Aasne Karinept_BR
dc.contributor.authorBartlett, William A.pt_BR
dc.contributor.authorFernández-Calle, Pilarpt_BR
dc.contributor.authorCoşkun, Abdurrahmanpt_BR
dc.contributor.authorDiaz-Garzon, Jorgept_BR
dc.contributor.authorJonker, Nielspt_BR
dc.contributor.authorZetterberg, Henrikpt_BR
dc.contributor.authorSandberg, Sverrept_BR
dc.contributor.authorCarobene, Annapt_BR
dc.contributor.authorBlennow, Kajpt_BR
dc.date.accessioned2024-11-09T06:40:51Zpt_BR
dc.date.issued2024pt_BR
dc.identifier.issn1552-5279pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/281052pt_BR
dc.description.abstractINTRODUCTION: Blood biomarkers have proven useful in Alzheimer’s disease (AD) research.However,littleisknownabouttheirbiologicalvariation(BV),whichimproves theinterpretation of individual-level data. METHODS: Wemeasuredplasmaamyloid beta (Aβ42, Aβ40), phosphorylated tau (p tau181, p-tau217, p-tau231), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) in plasma samples collected weekly over 10 weeks from 20 partici pantsaged40to60yearsfromtheEuropeanBiologicalVariationStudy.Weestimated within-(CVI)andbetween-subject(CVG)BV,analyticalvariation,andreferencechange values (RCV). RESULTS: Biomarkers presented considerable variability in CVI and CVG.Aβ42/Aβ40 hadthelowestCVI (≈3%)andp-tau181thehighest(≈16%), whileothersrangedfrom 6%to10%.MostRCVsrangedfrom20%to30%(decrease)and25%to40%(increase). DISCUSSION: BV estimates for AD plasma biomarkers can potentially refine their clinical and research interpretation. RCVs might be useful for detecting significant changes between serial measurements when monitoring early disease progression or interventions.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofAlzheimer's & dementia : the journal of the Alzheimer's Association. Hoboken, NJ. Vol. 20, no. 2 (Feb. 2024), p. 1284-1297pt_BR
dc.rightsOpen Accessen
dc.subjectAmyloiden
dc.subjectDoenças neurodegenerativaspt_BR
dc.subjectDoença de Alzheimerpt_BR
dc.subjectAnalytical variationen
dc.subjectBiomarcadorespt_BR
dc.subjectBiological variationen
dc.subjectProteína glial fibrilar ácidapt_BR
dc.subjectGlial fibrillary acidic proteinen
dc.subjectAmilóidept_BR
dc.subjectNeurofilament lighten
dc.subjectPlasma biomarkersen
dc.subjectProteínas taupt_BR
dc.subjectPhosphorylated tauen
dc.subjectReference change valuesen
dc.titleBiological variation estimates of Alzheimer’s disease plasma biomarkers in healthy individualspt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001207663pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
Nome:
001207663.pdf
Tamanho:
1.336Mb
Formato:
PDF
Descrição:
Texto completo (inglês)
Visualizar/abrir
   

Este item está licenciado na Creative Commons License

Mostrar registro simples